About Us

Consortium Overview

Funding Agency

Department of Defense - Congressionally Directed Medical Research Programs (CDMRP)
The CDMRP fills research gaps by funding high impact, high risk and high gain projects that other agencies may not venture to fund. While individual programs are unique in their focus, all of the programs managed by the CDMRP share the common goal of advancing paradigm shifting research, solutions that will lead to cures or improvements in patient care, or breakthrough technologies and resources for clinical benefit. The CDMRP strives to transform health care for Service Members and the American public through innovative and impactful research.
Learn more about CDMRP.
Alcohol and Substance Use Disorders Research Program (ASUDRP)
Alcohol and substance use disorders remain a concern for the American public and in particular for the military personnel and Veterans. The ASUDRP aims to investigate approaches for addressing alcohol and substance use disorders, especially when co-occurring with post-traumatic stress disorder (PTSD) and other psychological disorders.
Learn more about ASUDRP.

Pharmaceuticals for Alcohol and Substance Use Disorders Alliance (PASA)

The PASA objective is to identify promising potential treatments for alcohol and substance use disorders (ASUD) particularly in the presence of other psychological disorders including post-traumatic stress disorder (PTSD). The importance of this objective for the Department of Defense (DOD) is that Veterans and service members suffer from ASUD at rates significantly higher than the general population. Additionally, the military population is more likely to see ASUD in combination with PTSD and other similar psychological disorders including suicidality. Of particular concern is opioid use disorder (OUD) in Veterans. Veterans with PTSD appear to be more susceptible to develop OUD, and the prevalence of this is increasing. OUD and overdose death from opioids, exacerbated by the COVID-19 pandemic, continue to be a health care issue.

RTI International and Baylor College of Medicine initiated PASA in 2015 under an ASUDRP consortium award. The PASA Core solicits, funds, and participates in the conduct and analysis of non-clinical basic science studies, preclinical animal research studies, and early-phase clinical trials of potential treatment compounds. The intention of these studies is to provide early-stage evidence that these compounds are safe and potentially effective in treating ASUD, particularly in the presence of PTSD and other psychological disorders.

PASA is overseen by a Programmatic Panel comprising government and non-government representatives and subject matter experts.

Current ASUDRP Programmatic Panel Members

Melissa Mehalick, PhD
Military Operational Medicine Research Program/Joint Program Committee 5 (MOMRP/JPC-5)
Daniel Falk, PhD
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Lt. Col. Saul Freedman,
U.S. Air Force Medical Support Agency
Maj. Yosef Fufa,
Embedded Behavioral Health Clinic-Fort Hood, Texas
Shwe Gyaw, MD
National Institute on Drug Abuse (NIH/NIDA)
Lt. Cmdr. Heather Hauck,
US Navy, MD
US Naval Hospital, Rota, Spain
Christopher Johnson, MSW
US Navy Bureau of Medicine and Surgery
Elyse Katz, PhD
US Army Medical Materiel Development Activity (USAMMDA)
Jane Olien, LCSW, BCD
Defense Health Agency Medical Affairs/Behavioral Health Clinical Operations
Marisa Roberto, PhD
The Scripps Research Institute
Jayanthi Sankar, PhD
U.S. Department of Veterans Affairs Office of Research and Development
Nancy Skopp, PhD
Defense Health Agency Psychological Health Center of Excellence

CDMRP Leadership

Michelle Lane, LCSW-C, CT
CDMRP Program Manager
Katherine Perez-Morera, PharmD
CDMRP Science Officer
Back to Top